Association of Diabetes With All-Cause and Cause-Specific Mortality in Asia
A Pooled Analysis of More Than 1 Million Participants

Jae Jeong Yang, PhD; Danxia Yu, PhD; Wanqing Wen, MD; Eiko Saito, PhD; Shafiu Rahman, MSc; Xiao-Ou Shu, PhD; Yu Chen, PhD; Prakash C. Gupta, PhD; Dongfeng Gu, PhD; Shoichiro Tsugane, PhD; Yong-Bing Xiang, MD; Yu-Tang Gao, MD; Jin-Min Yuan, PhD; Akiko Tamakoshi, PhD; Fujiko Irie, PhD; Atsuko Sakadane, PhD; Yasutake Tomata, PhD; Seiki Kanemura, PhD; Ichiro Tsuji, PhD; Keitaro Matsuo, PhD; Chien-Jen Chen, ScD; Woon-Puay Koh, PhD; Myung-Hee Shin, PhD; Sue K. Park, PhD; Pei-Ei Wu, PhD; You-Lin Qiao, PhD; Norie Sawada, PhD; Hong-Lan Li, MD; Paolo Boffetta, MD; Manami Inoue, MD; Daehee Kang, PhD; John D. Potter, PhD; Wei Zheng, PhD

Abstract

IMPORTANCE Asia is home to the largest diabetic populations in the world. However, limited studies have quantified the association of diabetes with all-cause and cause-specific mortality in Asian populations.

OBJECTIVES To evaluate the association of diabetes with all-cause and cause-specific mortality in Asia and to investigate potential effect modifications of the diabetes-mortality associations by participants’ age, sex, education level, body mass index, and smoking status.

DESIGN, SETTING, AND PARTICIPANTS This pooled analysis incorporated individual participant data from 22 prospective cohort studies of the Asia Cohort Consortium conducted between 1963 and 2006. A total of 1,002,551 Asian individuals (from mainland China, Japan, South Korea, Singapore, Taiwan, India, and Bangladesh) were followed up for more than 3 years. Cohort-specific hazard ratios and 95% confidence intervals for all-cause and cause-specific mortality were estimated using Cox regression models and then pooled using random-effects meta-analysis. Analysis was conducted between January 10, 2018, and August 31, 2018.

EXPOSURES Doctor-diagnosed diabetes, age, sex, education level, body mass index, and smoking status.

MAIN OUTCOMES AND MEASURES All-cause and cause-specific mortality.

RESULTS Of 1,002,551 participants (518,537 [51.7%] female; median [range] age, 54.0 [30.0-98.0] years), 148,868 deaths were ascertained during a median (range) follow-up of 12.6 (3.0-38.9) years. The overall prevalence of diabetes reported at baseline was 4.8% for men and 3.6% for women. Patients with diabetes had a 1.89-fold risk of all-cause death compared with patients without diabetes (hazard ratio [HR], 1.89; 95% CI, 1.74-2.04), with the highest relative risk of death due to diabetes itself (HR, 22.8; 95% CI, 18.5-28.1), followed by renal disease (HR, 3.08; 95% CI, 2.50-3.78), coronary heart disease (HR, 2.57; 95% CI, 2.19-3.02), and ischemic stroke (HR, 2.15; 95% CI, 1.85-2.51). The adverse diabetes-mortality associations were more evident among women (HR, 2.09; 95% CI, 1.89-2.32) than among men (HR, 1.74; 95% CI, 1.62-1.88) (P for interaction < .001) and more evident among adults aged 30 to 49 years (HR, 2.43; 95% CI, 2.08-2.84) than among adults aged 70 years and older (HR, 1.51; 95% CI, 1.40-1.62) (P for interaction < .001). A similar pattern of association

(continued)
Abstract (continued)

was found between diabetes and cause-specific mortality, with significant variations noted by sex and age.

CONCLUSIONS AND RELEVANCE This study found that diabetes was associated with increased risk of death from several diseases among Asian populations. Development and implementation of diabetes management programs are urgently needed to reduce the burden of diabetes in Asia.

JAMA Network Open. 2019;2(4):e192696. doi:10.1001/jamanetworkopen.2019.2696

Introduction

The global epidemic of diabetes has rapidly spread to every country in Asia. Currently, more than 230 million Asian individuals are living with diabetes, accounting for approximately 55% of the world’s diabetic population, and this number is expected to exceed 355 million by 2040. Two Asian countries, China and India, are home to the largest number of patients with diabetes in the world (110 million and 69.2 million, respectively). Three other Asian countries, Indonesia, Japan, and Bangladesh, are also ranked among the countries with the highest number of patients with diabetes worldwide. Given the increasing prevalence of obesity and the rapid adoption of a Westernized lifestyle in most Asian countries (especially developing countries), the diabetes epidemic will likely continue to impose a burden on public health systems across Asia.

Emerging evidence suggests that diabetes in Asia shows unique features: compared with their Western counterparts, Asian individuals develop diabetes at a younger age and at a lower body mass index (BMI) and have a greater risk of developing complications, which may cause premature death. In addition, there are differences in genetics, socioeconomic factors, and diabetes management approaches between Asia and other continents, which may lead to a varied influence of diabetes on mortality in Asia. However, limited studies have prospectively quantified the association of diabetes with all-cause and cause-specific mortality in Asian populations and/or have examined potential effect modifiers on the association. In this pooled analysis of 22 prospective cohort studies, we assessed the association of diabetes with all-cause and cause-specific mortality in more than 1 million Asian individuals from multiple countries and regions and further investigated potential effect modifications of diabetes-mortality associations by participants’ age, sex, education level, BMI, and smoking status.

Methods

Study Populations

This study includes 22 prospective cohort studies in multiple countries and regions—mainland China, Japan, South Korea, Singapore, Taiwan, India, and Bangladesh—participating in the Asia Cohort Consortium (ACC). Details of the ACC have been described elsewhere. Brief descriptions of participating cohorts are given in the eAppendix in the Supplement. All cohort studies and the current pooled analysis received approval from the ethics committees of the host institutions. All study participants provided informed consent to the parent cohort studies. Each cohort collected baseline and outcome data according to its study protocol. The ACC coordinating center obtained deidentified individual participant data from each cohort and harmonized it across cohorts. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

Exposure and Outcome Assessment

Data on self-reported doctor-diagnosed diabetes were collected at baseline in all participating cohorts and used in the previous ACC pooled analyses. The overall validity of self-reported
diabetes was evaluated in several participating cohorts, showing a very high specificity (approximately 99%) and a moderate sensitivity (approximately 62%). Information on types of diabetes was unavailable in the ACC; however, among one-third of patients with diabetes who reported their age at the first diagnosis, only 0.2% were diagnosed before the age of 20 years, which was consistent with a low prevalence of type 1 diabetes in Asia. Additionally, we excluded participants younger than 30 years at enrollment. Thus, nearly all patients with diabetes were diagnosed with type 2 diabetes. No clinical information, such as glucose levels and use of medications, was collected in most of the participating cohorts.

For mortality information, all study participants were followed up through data linkages to death certificates and/or active follow-up surveys. According to the International Classification of Diseases, Ninth Revision or International Classification of Diseases, Tenth Revision, the primary cause of death was coded for cause-specific mortality (eTable 1 in the Supplement). The Ibaraki Prefectural Health Study (Japan) ascertained the date of death without underlying causes; hence, it was only included in the analysis of all-cause mortality.

Statistical Analysis

Of the 1,154,333 individuals included in these cohorts, we excluded 94,460 with unknown status on diabetes at baseline and 7,889 with missing or incorrect information concerning vital status, duration of follow-up, or age at baseline (<30 years). To minimize the potential influence of underlying diseases other than diabetes on mortality risk, we further excluded data from the first 3 years of follow-up, including 49,433 participants who were followed up for less than 3 years. After these exclusions, 1,002,551 participants (484,014 men and 518,537 women) remained for the current analysis (Table 1).

A 2-stage individual participant data meta-analysis was applied. First, we evaluated the associations between diabetes and mortality in each cohort separately. Then, cohort-specific hazard ratios (HRs) and 95% confidence intervals were pooled using the random-effects meta-analysis method. Proportionality assumption was tested using the global goodness-of-fit test with Schoenfeld residuals in each cohort—there was no evidence of a violation. In the Cox models, age was treated as the time scale, using age at enrollment (entry) and age at the final follow-up (exit), which was either the date of death or the date of last contact (ie, end of follow-up or loss to follow-up), whichever came first. All Cox models were stratified by 5-year intervals of birth year and enrollment year to account for the difference in calendar time across study populations. Covariates included age at baseline (continuous), smoking status (current, former, and never), smoking pack-year (0, 0.1-20.0, 20.1-40.0, and >40.0 pack-years), educational attainment (no formal schooling, primary education, secondary education, college education, university graduate, and postgraduate), marital status (single, married, and other), residential area (urban and rural), and BMI (<18.50, 18.50-24.99, 25.00-29.99, and ≥30.00; calculated as weight in kilograms divided by height in meters squared). The proportion of missing covariates was less than 10% in most participating cohorts. Missing covariates were imputed using the median (for continuous variables) or mode (for categorical variables) values of cohort-specific nonmissing covariates. In the sensitivity analyses, we excluded participants who had a history of cardiovascular disease (CVD) or cancer (except for nonmelanoma skin cancer) at baseline. Furthermore, we excluded 1 country at a time from the meta-analysis to assess the robustness of the overall findings.

To estimate the overall risk of death associated with diabetes among Asian populations, we first compared cause-specific death rates between individuals with and without diabetes. Death rates by diabetes status were estimated with age- and sex-specific deaths and person-years at risk, which were standardized according to the age and sex distribution of the ACC populations. The diabetes-mortality association, measured using HRs and 95% CIs, was evaluated for all participants and by sex (men and women), age at baseline (30-49, 50-59, 60-69, and ≥70 years), educational attainment (less than primary school graduation, secondary school, trade or technical school, and university graduation or greater), BMI (18.50, 18.50-22.99, 23.00-24.99, and ≥25.00), and smoking status.
The interaction between diabetes and individual characteristics was tested by a 2-stage method\(^\text{17}\): the interactions were estimated in each cohort by using the likelihood ratio test entering a cross-product term of diabetes and the stratification variable. Then, the cohort-specific estimates (regression coefficients and variances) were pooled using random-effects meta-analysis. A 2-sided \(P\) value of less than .05 was considered statistically significant. All statistical procedures were conducted using SAS statistical software version 9.3 (SAS Institute Inc).

## Results

During a median (range) follow-up of 12.6 (3.0-38.9) years, 148,868 deaths were ascertained among 1,002,551 participants (518,537 [51.7%] female; median [range] age, 54.0 [30.0-98.0] years). The overall prevalence of self-reported diabetes was 4.8% for men and 3.6% for women (Table 1).

### Table 1. Characteristics of Participating Cohorts in the Asia Cohort Consortium

| Cohort | Participants, No.\(^a\) | Baseline Survey Dates | Follow-up, Median (Range), y\(^b\) | Women, No. (%) | Age at Baseline, Median (Range), y | Diabetes, No. (%) | Deaths, No. |
|--------|---------------------------|-----------------------|----------------------------------|----------------|----------------------------------|-------------------|------------|
| **Mainland China** | | | | | | | |
| China National Hypertension Survey Epidemiology Follow-up Study | 138,640 | 1990-1992 | 8.2 (3.0-9.9) | 70,737 (51.0) | 54.0 (40.0-91.0) | 1400 (2.1) | 1515 (2.1) | 12,453 |
| Shanghai Cohort Study | 17,703 | 1986-1989 | 18.0 (3.0-21.1) | NA | 55.0 (35.0-76.0) | 222 (1.3) | NA | 4607 |
| Shanghai Men's Health Study | 60,379 | 2001-2006 | 9.7 (3.0-13.4) | NA | 52.0 (40.0-75.0) | 3692 (6.1) | NA | 4346 |
| Shanghai Women's Health Study | 74,188 | 1996-2000 | 15.3 (3.0-18.4) | 74,188 (100.0) | 50.0 (40.0-70.0) | NA | 3172 (4.3) | 6903 |
| Linxian General Population Trial Cohort | 28,532 | 1984-1987 | 23.2 (3.0-25.8) | 15,929 (55.8) | 51.0 (30.0-81.0) | 18 (0.1) | 13 (0.1) | 15,320 |
| **Japan** | | | | | | | |
| 3 Prefecture Aichi Study | 20,529 | 1985-1985 | 15.2 (3.0-15.5) | 11,048 (55.8) | 53.0 (40.0-97.0) | 554 (5.8) | 368 (3.3) | 2867 |
| Ibaraki Prefectural Health Study | 95,537 | 1993-1994 | 12.3 (3.0-12.7) | 63,222 (66.2) | 60.0 (39.0-79.0) | 1255 (3.9) | 1416 (2.2) | 9721 |
| Japan Collaborative Cohort Study | 73,351 | 1988-1990 | 14.3 (3.0-16.0) | 42,820 (58.4) | 57.0 (40.0-79.0) | 2060 (6.8) | 1833 (4.3) | 9387 |
| Japan Public Health Center-Based prospective Study 1 | 42,548 | 1990-1992 | 22.6 (3.0-23.0) | 22,255 (52.3) | 50.0 (40.0-59.0) | 1114 (5.5) | 555 (2.5) | 7069 |
| Japan Public Health Center-Based prospective Study 2 | 55,530 | 1992-1995 | 19.7 (3.0-20.0) | 29,415 (53.0) | 55.0 (40.0-69.0) | 1980 (7.6) | 1906 (3.7) | 11,964 |
| 3 Prefecture Miyagi Study | 27,954 | 1984-1984 | 15.0 (3.0-15.0) | 15,679 (56.1) | 56.0 (40.0-98.0) | 879 (7.2) | 648 (4.1) | 5436 |
| Miyagi Cohort | 46,543 | 1990-1990 | 17.8 (3.0-17.8) | 24,311 (52.2) | 53.0 (40.0-64.0) | 1182 (5.3) | 771 (3.2) | 5340 |
| Ohsaki National Health Insurance Cohort Study | 45,217 | 1994-1994 | 13.2 (3.0-13.2) | 23,561 (52.1) | 62.0 (40.0-80.0) | 1568 (7.2) | 1357 (5.8) | 8141 |
| Life Span Study | 39,314 | 1963-1993 | 21.9 (3.0-38.9) | 20,994 (53.4) | 51.0 (30.0-97.0) | 1681 (9.2) | 1181 (5.6) | 20,073 |
| Takayama Study | 25,694 | 1992-1992 | 15.6 (3.0-15.6) | 14,217 (55.3) | 54.0 (35.0-97.0) | 840 (7.3) | 471 (3.3) | 4810 |
| **Korea** | | | | | | | |
| Korean Multi-center Cancer Cohort Study | 12,607 | 1993-2004 | 14.4 (3.0-20.5) | 7665 (60.8) | 56.0 (30.0-89.0) | 222 (4.5) | 360 (4.7) | 2260 |
| Seoul Male Cancer Cohort | 13,767 | 1992-1993 | 16.0 (3.1-16.0) | NA | 49.0 (31.8-82.0) | 423 (3.1) | NA | 836 |
| **Singapore** | | | | | | | |
| Singapore Chinese Health Study | 61,298 | 1993-1999 | 12.5 (3.0-14.9) | 34,494 (56.3) | 55.0 (43.0-83.0) | 2161 (8.1) | 3041 (8.8) | 8733 |
| **Taiwan** | | | | | | | |
| Community-Based Cancer Screening Project | 23,425 | 1991-1992 | 15.9 (3.0-16.9) | 11,703 (50.0) | 47.0 (30.0-66.0) | 318 (2.7) | 251 (2.1) | 2452 |
| Cardiovascular Disease Risk Factor Two-Township Study | 42,64 | 1990-1993 | 15.7 (3.0-17.2) | 23,811 (55.8) | 51.0 (30.0-91.0) | 71 (3.8) | 100 (4.2) | 741 |
| **Bangladesh** | | | | | | | |
| Health Effects for Arsenic Longitudinal Study | 8489 | 2000-2002 | 12.7 (3.0-13.5) | 4185 (49.3) | 40.0 (30.0-75.0) | 132 (3.1) | 121 (2.9) | 677 |
| **India** | | | | | | | |
| Mumbai Cohort Study | 87,042 | 1991-1997 | 5.7 (3.0-8.1) | 29,733 (34.2) | 50.0 (35.0-98.0) | 1511 (2.6) | 385 (1.3) | 4732 |
| **Total** | 1,002,551 | 1963-2006 | 12.6 (3.0-38.9) | 518,537 (51.7) | 54.0 (30.0-98.0) | 23,283 (4.8) | 18,654 (3.6) | 148,868 |

Abbreviation: NA, not available.

\(^a\) Includes only participants who were eligible for the current pooled analysis.

\(^b\) Median years of total follow-up time interval from study entry to the final date of last contact (end of follow-up, date of death, or loss to follow-up).
Diabetes was associated with a 1.89-fold increase in risk of death from all causes (HR, 1.89; 95% CI, 1.74-2.04) (Table 2). Specifically, patients with diabetes were at an increased risk of death from a wide range of diseases, with the highest relative risk for death due to diabetes itself (HR, 22.8; 95% CI, 18.5-28.1); followed by renal disease (HR, 3.08; 95% CI 2.50-3.78), including kidney failure (HR, 3.32; 95% CI, 2.67-4.12) and other renal disease (HR, 2.72; 95% CI, 198-3.74); coronary heart disease.

### Table 2. All-Cause and Cause-Specific Mortality Associated With Diabetes in Asian Populations

| Cause                        | Diabetes |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
|------------------------------|----------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
|                              | Deaths, No. | Death Rate per 1000 Person-Years | Deaths, No. | Death Rate per 1000 Person-Years | Adjusted HR (95% CI) |
| All causes                   | 12,465    | 166              | 136,403         | 126.4            | 1.89 (1.74-2.04) |
| Cardiovascular disease       |          |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Coronary heart disease       | 1,471     | 17.4             | 9,107           | 6.8              | 2.57 (2.19-3.02) |
| Stroke, all types            | 1,582     | 20.4             | 16,235          | 17.1             | 1.81 (1.61-2.04) |
| Ischemic stroke              | 576       | 7.4              | 4,815           | 7.4              | 2.15 (1.85-2.51) |
| Hemorrhage stroke            | 470       | 7.4              | 6,433           | 5                | 1.38 (1.17-1.62) |
| Other                        | 1,094     | 15.7             | 12,181          | 16.5             | 1.73 (1.53-1.96) |
| Endocrine, nutritional, and metabolic disease |          |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Diabetes                     | 1,456     | 17.1             | 1,165           | 0.6              | 22.8 (18.5-28.1) |
| Other                        | 31        | 1.2              | 681             | 0.6              | 1.68 (1.08-2.61) |
| Cancer                       |          |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Lung                         | 501       | 5.2              | 8,830           | 4.8              | 0.98 (0.89-1.07) |
| Breast                       | 76        | 0.9              | 1,071           | 0.9              | 1.74 (1.28-2.38) |
| Colorectal                    | 359       | 3.3              | 4,274           | 2.9              | 1.30 (1.16-1.46) |
| Stomach                       | 394       | 4.8              | 6,880           | 4.2              | 1.10 (0.96-1.25) |
| Liver                         | 459       | 4.9              | 4,067           | 2.5              | 1.89 (1.59-2.24) |
| Pancreas                      | 224       | 2.6              | 2,393           | 1.3              | 1.55 (1.31-1.84) |
| Gallbladder                   | 136       | 1.4              | 1,628           | 1                | 1.38 (1.16-1.65) |
| Female reproductive organs    | 67        | 0.9              | 1,160           | 0.7              | 1.21 (0.93-1.56) |
| Other                         | 723       | 8.7              | 10,430          | 7.4              | 1.22 (1.13-1.32) |
| Renal disease                 |          |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Kidney failure                | 232       | 2.7              | 1,211           | 1.5              | 3.32 (2.67-4.12) |
| Other                         | 181       | 2.6              | 1,104           | 0.8              | 2.72 (1.98-3.74) |
| Digestive system disease      |          |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Liver disorder                | 227       | 3.7              | 2,234           | 1.8              | 2.24 (1.87-2.68) |
| Gallbladder, biliary tract, and pancreas | 45 | 0.5 | 452 | 2.8 | 2.04 (1.48-2.80) |
| Stomach, esophagus, and duodenum | 34 | 0.3 | 402 | 0.5 | 1.73 (1.20-2.49) |
| Other                         | 131       | 1.3              | 1,208           | 1.1              | 2.10 (1.63-2.70) |
| Respiratory disease           |          |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Pneumonia                     | 790       | 18.8             | 6,595           | 11.9             | 1.79 (1.51-2.11) |
| Asthma                        | 27        | 0.3              | 581             | 0.6              | 1.20 (0.81-1.79) |
| Chronic obstructive pulmonary disease | 100 | 0.7 | 2,549 | 1.8 | 0.78 (0.63-0.96) |
| Other                         | 232       | 2.2              | 2,336           | 2.8              | 1.59 (1.38-1.82) |
| Infectious disease            |          |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Tuberculosis                  | 38        | 0.5              | 802             | 0.9              | 2.28 (1.41-3.69) |
| Other                         | 162       | 8.5              | 1,701           | 1.1              | 2.00 (1.62-2.47) |
| Other known disease           |          |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
| Mental disorder               | 32        | 0.4              | 542             | 0.7              | 1.93 (1.22-3.05) |
| Nervous system disorder       | 63        | 0.6              | 1,193           | 1                | 1.10 (0.84-1.45) |
| Other                         | 697       | 10.4             | 10,060          | 16.5             | 1.42 (1.23-1.64) |
| Not specified                 | 901       | 7.8              | 23,781          | 13               | 1.73 (1.61-1.85) |

Abbreviation: HR, hazard ratio.

* Death rate per 1000 person-years, standardized by age and sex.

† Adjusted for age, sex, smoking status, smoking pack-years, education, marital status, rural vs urban residence, and obesity status and stratified by birth year (5-year groups) and enrollment year (5-year groups).

‡ Malignant neoplasms of vagina, cervix uteri, corpus uteri, uterus, ovary, vulva, and other female genital organs.

§ Liver cirrhosis, hepatic failure, chronic hepatitis, fibrosis, alcoholic or toxic liver disease, and other kinds of liver disorders.

¶ Unknown causes including missing and invalid data on cause of death.
(HR, 2.57; 95% CI, 2.19-3.02); tuberculosis (HR, 2.28; 95% CI, 1.41-3.69); liver disorder (HR, 2.24; 95% CI, 1.87-2.68); and ischemic stroke (HR, 2.15; 95% CI, 1.85-2.51). Significant positive associations with diabetes were also found for risk of death from hemorrhagic stroke, digestive system disease, certain cancers (eg, liver, breast, pancreas, gallbladder, and colon or rectum), infectious disease, and mental disorder. However, a significant inverse association was found between diabetes and death from chronic obstructive pulmonary disease.

We found some differences in the diabetes-mortality association by country and region: the relative risks were greater than 2.6-fold in Taiwan and rural China; approximately 2.2-fold in Bangladesh, Singapore, and urban China; and less than 2.0-fold in Japan, South Korea, and India (P for heterogeneity <.001) (eFigure in the Supplement). Furthermore, the magnitude of the diabetes-mortality association differed by sex, age, and smoking status among women (Table 3). The relative risk for all-cause mortality was greater among women (HR, 2.09; 95% CI, 1.89-2.32) than among men (HR, 1.74; 95% CI, 1.62-1.88) (P for interaction <.001) and greater among participants aged 30 to 49 years (HR, 2.43; 95% CI, 2.08-2.84) than for those aged 50 to 59 years (HR, 2.06; 95% CI, 1.83-2.31), 60 to 69 years (HR, 1.87; 95% CI, 1.71-2.05), and 70 years or older (HR, 1.51; 95% CI, 1.40-1.62) (P for interaction <.001). Among women only, the diabetes-mortality association was stronger among

Table 3. All-Cause Mortality Associated With Diabetes Stratified by Individual Characteristics in Asian Populations

| Characteristic                       | No. Diabetes Participants | No. Diabetes Death | Adjusted HR (95% CI)a | P Value for Interaction |
|--------------------------------------|---------------------------|--------------------|-----------------------|------------------------|
|                                      |                           |                    |                       |                        |
| Sex                                  |                           |                    |                       |                        |
| Men                                  | 23 283                    | 7231               | 1.74 (1.62-1.88)      | <.001                  |
| Women                                | 18 654                    | 5234               | 2.09 (1.89-2.32)      |                        |
| Age at baseline, y                   |                           |                    |                       |                        |
| <50                                  | 7386                      | 1106               | 2.43 (2.08-2.84)      | <.001                  |
| 50-59                                | 13 742                    | 3131               | 2.06 (1.83-2.31)      |                        |
| 60-69                                | 15 262                    | 5372               | 1.87 (1.71-2.05)      |                        |
| ≥70                                  | 55 47                     | 2856               | 1.51 (1.40-1.62)      |                        |
| Educational attainmentb              |                           |                    |                       |                        |
| ≤Primary school                      | 15 392                    | 5410               | 1.98 (1.74-2.24)      | .72                    |
| Secondary school                     | 10 584                    | 2820               | 1.94 (1.74-2.17)      |                        |
| Trade or technical school            | 3814                      | 764                | 1.79 (1.65-1.95)      |                        |
| ≥University graduation               | 3369                      | 655                | 1.69 (1.47-1.94)      |                        |
| Body mass indexc                     |                           |                    |                       |                        |
| <18.5                                | 1500                      | 687                | 1.87 (1.62-2.15)      | .24                    |
| 18.5-22.9                            | 14 813                    | 4847               | 1.96 (1.77-2.16)      |                        |
| 23.0-24.9                            | 10 913                    | 3127               | 1.86 (1.69-2.04)      | .14                    |
| ≥25.0                                | 14 711                    | 3804               | 1.85 (1.69-2.02)      |                        |
| Smoking status for men               |                           |                    |                       |                        |
| Never                                | 6799                      | 1593               | 1.84 (1.64-2.08)      | .14                    |
| Former                               | 5237                      | 1778               | 1.62 (1.51-1.75)      |                        |
| Current                              | 11 247                    | 3860               | 1.70 (1.58-1.83)      |                        |
| Smoking status for women             |                           |                    |                       |                        |
| Never                                | 16 749                    | 4514               | 2.13 (1.93-2.36)      | .009                   |
| Former                               | 451                        | 177                | 1.98 (1.55-2.52)      |                        |
| Current                              | 1454                      | 543                | 1.81 (1.59-2.06)      |                        |

Abbreviation: HR, hazard ratio.

a Adjusted for age, sex, smoking status, smoking pack-years, education, marital status, rural vs urban residence, and obesity status and stratified by birth year (5-year groups) and enrollment year (5-year groups).

b Cohorts (3 Prefecture Aichi Study, 3 Prefecture Miyagi Study, Ibaraki Prefectural Health Study, Japan Public Health Center-Based Prospective Study 2, Korean Multi-center Cancer Cohort Study) without information on education were not included in the analysis.

c Calculated as weight in kilograms divided by height in meters squared.
those who had never smoked than among current smokers (HR, 2.13; 95% CI, 1.93-2.36 vs HR, 1.81; 95% CI, 1.59-2.06, respectively) (P for interaction = .009). No significant differences were found by smoking status among men, educational attainment, or BMI levels.

Potential modifying effects of sex, age, and BMI on the associations of diabetes with cause-specific mortality in Asian populations are shown in Table 4 and Table 5 and eTable 2 in the Supplement. Multiple CVD mortality outcomes (ie, total CVD, coronary heart disease, and ischemic stroke) and renal disease mortality showed stronger associations with diabetes among women than among men. Meanwhile, many mortality outcomes, including deaths due to CVD, digestive disease, respiratory disease, and infectious disease, showed stronger associations with diabetes among younger than among elderly adults. Moreover, the association of diabetes with risk of death due to diabetes itself was much stronger among those with a BMI less than 18.5 (HR, 95.4; 95% CI, 18.5-28.1).

### Table 4. Cause-Specific Mortality Associated With Diabetes Stratified by Individual Characteristics in Asian Populations: Death from Cardiometabolic Diseases

| Characteristic                   | Cardiac Disease | Coronary Heart Disease | Ischemic Stroke | Hemorrhagic Stroke | Diabetes Mellitus |
|----------------------------------|-----------------|------------------------|-----------------|-------------------|-------------------|
| All patients                     | 2.00 (1.76-2.29)| 2.57 (2.19-3.02)       | 2.15 (1.85-2.51)| 1.38 (1.17-1.62)  | 22.8 (18.5-28.1)  |
| Sex                              |                 |                        |                 |                   |                   |
| Men                              | 1.82 (1.58-2.09)| 2.22 (1.86-2.64)       | 1.74 (1.49-2.04)| 1.35 (1.12-1.62)  | 23.0 (17.6-30.0)  |
| Women                            | 2.30 (1.96-2.71)| 3.25 (2.64-4.00)       | 2.95 (2.29-3.78)| 1.41 (1.17-1.68)  | 20.5 (16.3-25.8)  |
| P value for interaction          | <.001           | <.001                  | <.002           | .74               | .54               |
| Age at baseline, y               |                 |                        |                 |                   |                   |
| <50                              | 2.95 (2.21-3.92)| 3.36 (2.29-4.94)       | 5.62 (2.37-13.4)| 2.42 (1.67-3.49)  | 29.0 (18.5-45.5)  |
| 50-59                            | 2.43 (2.00-2.96)| 3.04 (2.43-3.80)       | 3.09 (2.32-4.13)| 1.58 (1.24-2.00)  | 21.3 (16.4-27.7)  |
| 60-69                            | 1.96 (1.70-2.27)| 2.64 (2.15-3.23)       | 2.05 (1.75-2.40)| 1.45 (1.20-1.75)  | 20.3 (15.2-27.1)  |
| ≥70                              | 1.46 (1.30-1.64)| 1.92 (1.60-2.99)       | 1.66 (1.41-1.95)| 0.95 (0.74-1.23)  | 21.7 (15.6-30.2)  |
| P value for interaction          | <.001           | <.001                  | <.001           | <.001             | .10               |
| Educational attainment           |                 |                        |                 |                   |                   |
| ≤Primary school                  | 2.01 (1.64-2.45)| 2.84 (2.25-3.60)       | 2.15 (1.74-2.66)| 1.24 (1.02-1.51)  | 19.4 (15.5-24.3)  |
| Secondary school                 | 2.05 (1.75-2.39)| 2.47 (2.01-3.03)       | 2.69 (1.96-3.69)| 1.55 (1.25-1.92)  | 26.9 (19.3-37.7)  |
| Trade or technical school        | 2.12 (1.87-2.42)| 2.56 (2.03-3.23)       | 1.91 (1.30-3.53)| 2.00 (1.42-2.80)  | 23.1 (12.6-42.5)  |
| ≥University graduation           | 2.00 (1.57-2.56)| 2.26 (1.51-3.36)       | 1.76 (1.04-2.99)| 2.04 (1.34-3.11)  | 19.6 (12.2-31.5)  |
| P value for interaction          | <.001           | <.001                  | <.001           | <.001             | .10               |
| Body mass index                  |                 |                        |                 |                   |                   |
| <18.5                            | 1.76 (1.41-2.20)| 2.51 (1.65-3.82)       | 1.45 (0.66-3.17)| 1.39 (0.85-2.26)  | 95.4 (38.0-239.8) |
| 18.5-22.9                        | 2.09 (1.79-2.44)| 2.71 (2.26-3.26)       | 2.07 (1.73-2.48)| 1.59 (1.36-1.86)  | 33.5 (24.6-45.7)  |
| 23.0-24.9                        | 2.11 (1.84-2.43)| 2.65 (2.19-3.21)       | 2.56 (2.04-3.21)| 1.64 (1.26-2.13)  | 22.1 (18.3-26.7)  |
| ≥25.0                            | 1.89 (1.61-2.21)| 2.47 (2.02-3.01)       | 2.21 (1.78-2.75)| 1.20 (0.86-1.66)  | 13.2 (10.7-16.4)  |
| P value for interaction          | .20             | .16                     | .39             | .07               | <.001             |
| Smoking status for men           |                 |                        |                 |                   |                   |
| Never                            | 2.04 (1.67-2.49)| 2.69 (2.08-3.46)       | 1.76 (1.14-2.71)| 1.38 (0.94-2.02)  | 25.8 (18.2-36.4)  |
| Former                           | 1.67 (1.37-2.05)| 1.98 (1.52-2.59)       | 1.87 (1.45-2.42)| 1.69 (1.27-2.23)  | 23.9 (15.6-36.7)  |
| Current                          | 1.81 (1.58-2.07)| 2.24 (1.89-2.65)       | 1.81 (1.52-2.16)| 1.41 (1.19-1.68)  | 21.1 (15.5-28.9)  |
| P value for interaction          | .63             | .19                     | .59             | .72               | .19               |
| Smoking status for women         |                 |                        |                 |                   |                   |
| Never                            | 2.35 (1.99-2.78)| 3.34 (2.73-4.08)       | 2.83 (2.21-3.62)| 1.42 (1.17-1.73)  | 20.4 (16.3-25.5)  |
| Former or current                | 1.97 (1.55-2.51)| 2.91 (2.06-4.12)       | 3.12 (1.83-5.32)| 1.48 (1.03-2.12)  | 15.1 (10.0-22.9)  |
| P value for interaction          | .48             | .14                     | .37             | .78               | .17               |

Abbreviation: HR, hazard ratio.

a Adjusted for age, sex, smoking status, smoking pack-years, education, marital status, rural vs urban residence, and obesity status and stratified by birth year (5-year groups) and enrollment year (5-year groups).

b Cohorts (3 Prefecture Aichi Study, 3 Prefecture Miyagi Study, Ibaraki Prefectural Health Study, Japan Public Health Center-Based Prospective Study 2, Korean Multi-center Cohort Study) without information on education were not included in the analysis.

c Calculated as weight in kilograms divided by height in meters squared.

d Former and current smokers were collapsed into 1 category to improve the stability of the point estimate.
than among those with a BMI of 25.0 or greater (HR, 13.2; 95% CI, 10.7-16.4) (P for interaction < .001).

Sensitivity analyses showed that (1) the association between diabetes and mortality did not change when we excluded the participants who had a history of CVD or cancer (eTable 3 in the Supplement) and (2) our overall results were not driven by the results from any single cohort or country (eTable 4 in the Supplement).

Discussion

This pooled analysis of more than 1 million individuals from 22 Asian cohort studies showed that diabetes is associated with substantially increased risk of death from several diseases, particularly diabetes itself, renal disease, coronary heart disease, and ischemic stroke. Moreover, the magnitude

| Characteristic | Adjusted HR (95% CI) | Total Cancer | Renal Disease | Digestive Disease | Respiratory Disease | Infectious Disease |
|----------------|----------------------|--------------|---------------|-------------------|--------------------|--------------------|
| All patients   | 1.21 (1.13-1.29)     | 3.08 (2.50-3.78) | 1.98 (1.73-2.25) | 1.45 (1.29-1.63) | 1.96 (1.59-2.41) |
| Sex            |                      |              |               |                   |                    |                    |
| Men            | 1.20 (1.13-1.29)     | 2.85 (2.23-3.66) | 2.02 (1.78-2.30) | 1.50 (1.35-1.68) | 1.95 (1.50-2.54) |
| Women          | 1.23 (1.12-1.36)     | 3.44 (2.66-4.45) | 1.95 (1.63-2.33) | 1.52 (1.25-1.83) | 2.09 (1.62-2.70) |
| P value for interaction | .50 | .91 | .53 | .86 |
| Age at baseline, y |          |              |               |                   |                    |                    |
| <50            | 1.24 (1.10-1.40)     | 9.65 (5.04-18.5) | 2.90 (2.21-3.82) | 3.60 (2.36-5.48) | 3.66 (2.00-6.67) |
| 50-59          | 1.30 (1.16-1.45)     | 5.09 (3.71-6.97) | 2.53 (1.94-3.30) | 2.00 (1.70-2.36) | 2.68 (1.81-3.95) |
| 60-69          | 1.18 (1.08-1.30)     | 2.85 (2.03-4.00) | 1.85 (1.56-2.19) | 1.50 (1.27-1.76) | 1.88 (1.43-2.47) |
| ≥70            | 1.18 (1.07-1.29)     | 2.10 (1.64-2.69) | 1.52 (1.18-1.97) | 1.18 (1.02-1.36) | 2.32 (1.64-3.28) |
| P value for interaction | .11 | .66 | <.001 | <.001 | .04 |
| Educational attainment |          |              |               |                   |                    |                    |
| ≤Primary school | 1.20 (1.08-1.33)     | 3.44 (2.51-4.72) | 1.83 (1.47-2.29) | 1.41 (1.19-1.68) | 2.20 (1.72-2.81) |
| Secondary school | 1.28 (1.16-1.41)     | 3.57 (2.53-5.03) | 2.40 (1.89-3.06) | 1.75 (1.44-2.12) | 2.29 (1.47-3.58) |
| Trade or technical school | 1.27 (1.10-1.46)     | 3.19 (1.83-5.58) | 2.97 (1.91-4.62) | 1.69 (1.10-2.61) | 2.14 (1.26-3.63) |
| ≥University graduation | 1.08 (0.91-1.28)     | 2.45 (1.87-6.91) | 2.76 (1.70-4.49) | 1.66 (0.96-2.87) | 1.91 (0.67-5.46) |
| P value for interaction | .88 | .81 | .02 | .47 | .84 |
| Body mass index |          |              |               |                   |                    |                    |
| <18.5          | 1.36 (1.14-1.62)     | 4.29 (2.68-6.86) | 2.80 (1.71-4.60) | 1.24 (0.95-1.60) | 2.22 (0.98-5.03) |
| 18.5-22.9      | 1.25 (1.15-1.36)     | 3.59 (2.66-4.86) | 2.07 (1.59-2.68) | 1.48 (1.27-1.73) | 2.07 (1.54-2.78) |
| 23.0-24.9      | 1.20 (1.09-1.33)     | 2.91 (2.33-3.63) | 2.26 (1.83-2.78) | 1.66 (1.45-1.89) | 2.42 (1.76-3.33) |
| ≥25.0          | 1.23 (1.10-1.38)     | 3.09 (2.26-4.24) | 2.04 (1.65-2.51) | 1.64 (1.34-2.00) | 2.20 (1.61-3.01) |
| P value for interaction | .95 | .09 | .37 | .007 | .49 |
| Smoking status for men |          |              |               |                   |                    |                    |
| Never          | 1.18 (1.00-1.40)     | 3.48 (2.51-4.83) | 2.31 (1.68-3.19) | 1.71 (1.40-2.10) | 2.55 (1.58-4.12) |
| Former         | 1.25 (1.13-1.38)     | 2.32 (1.64-3.28) | 1.85 (1.33-2.58) | 1.62 (1.42-1.85) | 2.33 (1.61-3.35) |
| Current        | 1.19 (1.09-1.29)     | 2.90 (2.05-4.11) | 2.45 (2.01-2.98) | 1.47 (1.26-1.72) | 2.02 (1.53-2.66) |
| P value for interaction | .39 | .42 | .18 | .09 | .55 |
| Smoking status for women |          |              |               |                   |                    |                    |
| Never          | 1.27 (1.16-1.40)     | 3.46 (2.62-4.59) | 1.84 (1.53-2.22) | 1.59 (1.30-1.95) | 2.17 (1.63-2.89) |
| Former or current | 1.07 (0.89-1.28)     | 3.65 (2.31-5.77) | 2.82 (1.81-4.41) | 1.47 (1.03-2.11) | 2.45 (1.09-5.50) |
| P value for interaction | .07 | .19 | .03 | .23 | .54 |

Abbreviation: HR, hazard ratio.

a Adjusted for age, sex, smoking status, smoking pack-years, education, marital status, rural vs urban residence, and obesity status and stratified by birth year (5-year groups) and enrollment year (5-year groups).

b Cohorts (3 Prefecture Aichi Study, 3 Prefecture Miyagi Study, Ibaraki Prefectural Health Study, Japan Public Health Center-Based Prospective Study2, Korean Multi-center Cohort Study) without information on education were not included in the analysis.

c Calculated as weight in kilograms divided by height in meters squared.

d Former and current smokers were collapsed into 1 category to improve the stability of the point estimate.
of the associations varied by sex, age, BMI, and smoking status. Women and middle-aged adults showed higher diabetes-related risk of death from all causes, total CVD, coronary heart disease, ischemic stroke, and renal disease than men and older adults. Among women, the risk for all-cause mortality associated with diabetes appeared stronger among those who had never smoked than among current or former smokers. The relative risk of death due to diabetes itself was much stronger among individuals who were underweight than among those who were overweight or obese.

Previous studies have reported that diabetes leads to an approximate 2-fold risk for all-cause mortality, but the magnitude of the association seems to vary by study. Generally, studies conducted in Western populations reported HRs of 1.15 to 1.90 for all-cause mortality associated with diabetes. Meanwhile, studies conducted in developing countries reported greater HRs, such as 2.00 in mainland China (1.83 in urban areas and 2.17 in rural areas) and 1.9 to 5.4 in Mexico. A recent meta-analysis including 709,503 participants from Western populations and 271,290 Asian individuals (mostly from South Korean) reported an HR for all-cause mortality of 1.69. Our study includes other Asian populations and has a much larger sample size, enabling us to assess associations of diabetes with a larger number of mortality outcomes and potential modifiers in a broader Asian population. The variation in the magnitude of the diabetes-mortality association may be attributed, in part, to differences in diabetes care across populations. Many Asian patients with diabetes, especially those living in less-developed areas, fail to achieve optimal glycemic control and vascular protection owing to a lack of access to health care, antidiabetic medications, and education on diabetes management.

For cause-specific mortality, diabetes was associated with a high relative risk of death from diabetes itself in Asian populations. The excess risks observed in our study are exceptionally high compared with those observed in the United States and in other countries. Furthermore, Asian diabetic populations were much more likely to die from renal disease, the major complication of diabetes, which is in line with the results from studies conducted in low-income countries. Evidence has indicated that Asian individuals are more susceptible to insulin resistance, early-onset type 2 diabetes and diabetes unrelated to obesity, and other metabolic disorders (eg, hypertension, hyperlipidemia, and visceral obesity) than populations with European ancestry. It is possible that these Asian-specific diabetes phenotypes are associated with a poor prognosis for diabetes and/or elevated risks of acute and chronic complications such as diabetic ketoacidosis and renal failure. Developing and implementing Asian-specific comprehensive diabetes management programs should help reduce mortality due to diabetes itself and/or its complications.

Consistent with the previous report from the ACC and other Asian studies, we observed that diabetes is associated with an increased risk of cancer mortality. In site-specific analyses, we found a positive association with liver, pancreas, and breast cancer, with an etiologic component that includes insulin resistance and obesity, which is in line with previous studies. Other findings for a positive association of diabetes with risk of death due to liver disorder; pancreas, gallbladder, and biliary tract-related disease; infection; and mental disorder are supported by previous studies. The pathogenesis of type 2 diabetes involves insulin resistance and impaired insulin secretion by β-cell dysfunction. Insulin secretion is modulated by the interplay of the pancreas with other organs and tissues such as liver, brain, digestive tracts, and adipose and muscle tissues. Our findings indicate an increased risk of death due to diseases of these insulin-related organs and tissues among patients with diabetes, highlighting the multifactorial and complicated effect of diabetes and the need for comprehensive health care strategies aimed at the effective management of diabetes and its complications.

We found that the association between diabetes and mortality in Asia varies by sex, age, and BMI, which is supported by previous findings. A previous study suggested that sex difference in the diabetes-mortality association may be attributed, in part, to sex hormones such as estrogens and androgens. It is also possible that the higher relative risk among women than among men, especially for CVD and renal disease mortality, may reflect gender inequality in diabetes care. Even in developed Western countries, female patients are less likely than male patients to receive optimal care and adhere
to recommended treatment. Our findings for a stronger association of diabetes with risk of death (both all-cause and cause-specific) in younger populations than in elderly populations are also supported by previous studies. These findings are perhaps not surprising because early-onset type 2 diabetes (ie, onset before middle age) is more closely associated with macrovascular cardiovascular complications than late-onset diabetes. Of note, given the increasing prevalence of early-onset diabetes in Asia, the burden of premature death associated with diabetes is unfailingly projected to increase in the near future. In addition, the risk of diabetes mortality is much stronger among underweight individuals in Asian populations. Underweight patients may reflect the severity of diabetes and/or the presence of complications due to the poor management of the disease. The significant differences in the diabetes-mortality associations by individual characteristics highlight the need for further attention to vulnerable groups, such as women and young or underweight patients with diabetes, when implementing diabetes management plans at a population level.

Strengths and Limitations

To our knowledge, this is the largest prospective investigation of the impact of diabetes on all-cause and cause-specific mortality among Asian populations. In contrast to previous studies that were limited mostly to Asian individuals from developed countries, our study populations were composed of Asian individuals from multiple countries and regions at various levels of economic development. The large sample size and the availability of individual participant data of more than 1 million Asian individuals from 22 prospective cohort studies yields great statistical power to assess potential variations in the diabetes-mortality associations by participants’ characteristics. However, we acknowledge several study limitations. First, data on diabetes diagnosis by their doctors were self-reported at baseline. It is possible that some patients who were not aware of their diabetes diagnosis at baseline or were diagnosed with diabetes during the cohort follow-up have been misclassified into the reference group, which could have attenuated the association. The validity of self-reported data in diabetes classification showed a sensitivity of approximately 62% and a specificity of approximately 99% in several participating cohorts. With a relatively low prevalence of diabetes in the Asian population, a low sensitivity has less impact on study results than a low specificity. Second, baseline surveys were conducted at different time periods (1963-2006); thus, our results may potentially be influenced by recent changes in diabetes diagnosis and treatment and lifestyle transitions in some Asian countries. To minimize potential time and period effects, our models were stratified by cohort enrollment year and participants’ birth year. Future studies using more recent data on diabetes diagnosis, treatment, and lifestyle factors could further evaluate the association of diabetes with mortality outcomes in Asia. Third, we cannot rule out potential influence of residual confounding on our study results, as data on some potential confounding factors were not collected from some cohort members and, thus, could not be adjusted in our study. Fourth, our participants may not fully represent each country or region. In particular, most participating cohorts came from East Asia; thus, the number of South Asian individuals is relatively small. Also, only individuals who are participants of the ACC cohorts are included in the analyses. However, we found comparable risk estimates and similar patterns of the diabetes-mortality association in each country or region when compared with the previous reports, providing some assurance for the overall external validity of our findings.

Conclusions

The diabetes epidemic in Asia is expected to continue to accelerate; thus, many Asian individuals will live with diabetes and its complications. Diabetes substantially increases the risk of premature death from several diseases among Asian populations, and the mortality burden associated with diabetes is particularly evident in women and patients with early-onset disease. Our findings suggest the urgent need for developing diabetes management programs that are tailored to Asian populations and the subsequent strong implementation of these programs in Asia.
Association of Diabetes With All-Cause and Cause-Specific Mortality in Asia

ARTICLE INFORMATION
Accepted for Publication: February 26, 2019.
Published: April 19, 2019. doi:10.1001/jamanetworkopen.2019.2696
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Yang JJ et al. JAMA Network Open.

Corresponding Author: Wei Zheng, MD, PhD, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, 2525 West End Ave, Eighth Floor, Nashville, TN 37203-1738 (wei.zheng@vanderbilt.edu).

Author Affiliations: Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee (Yang, Yu, Wen, Shu, Cai, Zheng); Division of Cancer Statistics Integration, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan (Saito); Department of Global Health Policy, Graduate School of Medicine, University of Tokyo, Tokyo, Japan (Rahman); Department of Population Health, New York University School of Medicine, New York (Y. Chen); Department of Environmental Medicine, New York University School of Medicine, New York (Y. Chen); Healis-Sekhsaria Institute for Public Health, Mahape, Navi Mumbai, India (Gupta, Pednekar); Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China (Gu); Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan (Tsugane, Sawada, Inoue); State Key Laboratory of Oncogene and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China (Xiang, Y.-T. Gao, Li, J. Gao); Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China (Xiang, Y.-T. Gao, Li, J. Gao); Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania (Yuan, Wang); Graduate School of Medicine, Hokkaido University, Sapporo, Japan (Tamakoshi); Department of Health and Welfare, Ibaraki Prefectural Office, Mito, Japan (Irie); Radiation Effects Research Foundation, Hiroshima, Japan (Sadakane, Grant); Tohoku University Graduate School of Medicine, Sendai, Japan (Tomata, Kanemura, Tsuji, Sugawara, Zhang); Division of Molecular & Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya, Japan (Matsuo, Ito); Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan (Matsuo, Ito); Graduate School of Medicine, Gifu University, Gifu City, Japan (Nagata, Wada); Academy Sinica, Taipei City, Taiwan (C.-J. Chen); Health Services and Systems Research, Duke-NUS Medical School Singapore, Singapore, Republic of Singapore (Koh); Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Republic of Singapore (Koh, Chia); Department of Social and Preventive Medicine, Sangkyounkwon University School of Medicine, Seoul, South Korea (Shin); Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea (Park, Ahn, Yoo, Kang); Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea (Park, Kang); Cancer Research Institute, Seoul National University, Seoul, South Korea (Park, Kang); Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei City, Taiwan (Wu); National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China (Qiao, Fan); Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana (He); Department of Public Health, Dokkyo Medical University School of Medicine, Mibu, Japan (Sairenchi); Institute of Biomedical Sciences, Academia Sinica, Taipei City, Taiwan (Shen, Pan); College of Public Health, China Medical University, Taichung, Taiwan, (Shen); School of Medicine & Big Data Research Center, Fu Jen Catholic University, Taipei City, Taiwan (You); Armed Forces Capital Hospital, Seongnam, South Korea (Yoo); Department of Health Studies, University of Chicago, Chicago, Illinois (Ashan); Department of Medicine, University of Chicago, Chicago, Illinois (Ashan); Department of Human Genetics, University of Chicago, Chicago, Illinois (Ashan); Cancer Research Center, University of Chicago, Chicago, Illinois (Ashan); Icahn School of Medicine at Mount Sinai, New York, New York (Boffetta); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington (Potter); Centre for Public Health Research, Massey University, Wellington, New Zealand (Potter); Department of Epidemiology, University of Washington, Seattle (Potter).

Author Contributions: Dr Zheng had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Yang and Yu contributed equally to the study.

Concept and design: Zheng.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Yang, Yu, Zheng.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Yang, Yu, Wen, Zheng.

Administrative, technical, or material support: Saito, Rahman, Shu, Y. Chen, Gupta, Gu, Tsugane, Xiang, Y.-T.Gao, Yuan, Tamakoshi, Irie, Sadakane, Tomata, Kanemura, Tsuji, Matsuo, Nagata, C.-J. Chen, Koh, Shin, Park, Wu, Qiao,
Supervision: Zheng.

Conflict of Interest Disclosures: Dr Shu reported grants from the National Cancer Institute during the conduct of the study. Dr Yuan reported grants from the National Institutes of Health during the conduct of the study. Dr Tamakoshi reported grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Ministry of Health, Labour and Welfare, Health and Labor Sciences during the conduct of the study. Dr Grant reported research support from the US Department of Energy and research support from Japan's Ministry of Health, Labour and Welfare outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by research funds from the Anne Potter Wilson Chair endowment and National Institutes of Health (NIH) grants (UM1CA182910 to Dr Zheng and UM1CA173640 to Dr Shu) at Vanderbilt University Medical Center. Participating cohort studies in the consortium are as follows: China National Hypertension Survey Epidemiology Follow-up Study (funded by American Heart Association grant 9750612N, National Heart, Lung, and Blood Institute grant U01-HL072507, and the Chinese Academy of Medical Sciences); Shanghai Cohort Study (funded by NIH grants RO1CA0403092, RO1CA144034, and UM1CA182876); Shanghai Men's Health Study (funded by NIH grant R01-CA82729); Shanghai Women's Health Study (funded by NIH grant R37-CA70867); Korea Multi-center Cancer Cohort (funded by Ministry of Education, Science and Technology, Korea, National Research Foundation of Korea grant 2009-0087452); Seoul Male Cancer Cohort (funded by National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea grant OS20160-1); Singapore Chinese Health Study (funded by NIH grants RO1CA55069, R35CA53890, RO1CA80205, RO1CA144034, and UM1CA182876); Community-Based Cancer Screening Project (funded by the National Science Council and Department of Health, Taiwan); Cardiovascular Disease Risk Factor Two-Township Study (funded by Department of Health, Taiwan, grants DOH80-27, DOH81-021, DOH8202-1027, DOH83-02-015, and DOH84-02-06); Health Effects of Arsenic Longitudinal Study (funded by NIH grants P42ES010349, RO1CA02484, and RO1CA07431); and Mumbai Cohort Study (funded by the International Agency for Research on Cancer, Clinical Trials Service Unit/Oxford University, and the World Health Organization); and Life Span Study (funded by the Radiation Effects Research Foundation, Hiroshima and Nagasaki, Japan, a private, nonprofit foundation funded by the Japanese Ministry of Health, Labour and Welfare and the US Department of Energy (DOE), the latter in part through DOE grant DE-HS0000031 to the National Academy of Sciences, and RERF Research Protocol RP-A03-10. The Three Prefecture Cohort Study Aichi, Ibaraki Prefectural Health Study, Japan Public Cohort Collaborative Study, Japan Public Health Center-based Prospective Study, Three Prefecture Cohort Study Miyagi, Miyagi Cohort Study, and Ohsaki National Health Insurance Cohort Study are supported by the Grant-in-aid for Cancer Research, Grant for the Third Term Comprehensive Control Research for Cancer, Grant for Health Services, Grant for Medical Services for Aged and Health Promotion, and Grant for Comprehensive Research on Cardiovascular and Life-style Related Diseases from the Ministry of Health, Labour and Welfare, Japan; and the Grant for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan. The Japan Public Health Center-Based Prospective Study and Takayama Study are also supported by the National Cancer Center Research and Development Fund.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank all research team members and participants of each cohort study for their contribution to this research. Marshal S. Younger, BA, Vanderbilt University Medical Center, assisted in preparing the manuscript. He did not receive extra compensation for his contribution other than his salary as an employee of the Vanderbilt University Medical Center.

REFERENCES
1. Ramachandran A, Ma RCW, Snehalatha C. Diabetes in Asia. Lancet. 2010;375(9712):408-418. doi:10.1016/S0140-6736(09)60937-5
2. International Diabetes Federation IDF Diabetes Atlas. Epidemiology and Morbidity. International Diabetes Federation http://www.diabetesatlas.org. Accessed January 30, 2017.
3. Nanditha A, Ma RCW, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care. 2016;39(3):472-485. doi:10.2337/dc15-1536
4. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249-1257. doi:10.2337/dc11-0442
5. Yoon K-H, Lee J-H, Kim J-W, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681-1688. doi:10.1016/S0140-6736(06)69703-1
6. Yusuf S, Islam S, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231-1243. doi:10.1016/S0140-6736(11)61215-4

7. Qi Q, Wang X, Strizich G, Wang T. Genetic determinants of type 2 diabetes in Asians. Int J Diabetol Vasc Dis Res. 2015;5(suppl 1). doi:10.19070/2328-353X-SI01001

8. Zheng W, McLerran DF, Rolland B, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011;364(8):719-729. doi:10.1056/NEJMoa1010679

9. Boffetta P, McLerran D, Chen Y, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One. 2011;6(6):e19930. doi:10.1371/journal.pone.0019930

10. Chen Y, Wu F, Saito E, et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia. 2017;60(6):1022-1032. doi:10.1007/s00125-017-4229-z

11. Chen Y, Ahsan H, Slavkovich V, et al. No association between arsenic exposure from drinking water and diabetes mellitus: a cross-sectional study in Bangladesh. Environ Health Perspect. 2010;118(9):1299-1305. doi:10.1289/ehp.0901559

12. Waki K, Noda M, Sasaki S, et al. JPHC Study Group. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort I. Diabet Med. 2005;22(3):323-331. doi:10.1111/j.1464-5491.2004.01403.x

13. Villegas R, Shu XO, Yang G, et al. Energy balance and type 2 diabetes: a report from the Shanghai Women's Health Study. Nutr Metab Cardiovasc Dis. 2009;19(3):190-197. doi:10.1016/j.numecd.2008.06.003

14. DIAMOND Project Group. Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med. 2006;23(8):857-866. doi:10.1111/j.1464-5491.2006.01925.x

15. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. 2017;36(5):855-875. doi:10.1002/sim.7141

16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. doi:10.1016/0197-4566(86)90046-2

17. Hua H, Burke DL, Crowther MJ, Ensor J, Tudur Smith C, Riley RD. One-stage individual participant data meta-analysis models: estimation of treatment-covariate interactions must avoid ecological bias by separating out within-trial and across-trial information. Stat Med. 2017;36(5):772-789. doi:10.1002/sim.7171

18. Bragg F, Holmes MV, Iona A, et al; China Kadoorie Biobank Collaborative Group. Association between diabetes and cause-specific mortality in rural and urban areas of China. JAMA. 2017;317(3):280-289. doi:10.1001/jama.2016.19720

19. Alegre-Díaz J, Herrington W, López-Cervantes M, et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med. 2016;375(20):1961-1971. doi:10.1056/NEJMoa1605368

20. Tancredi M, Rosengren A, Svensson A-M, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732. doi:10.1056/NEJMoa1504347

21. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-841. doi:10.1056/NEJMoa1008862

22. Woodward M, Zhang X, Barzi F, et al; Asia Pacific Cohort Studies Collaboration. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care. 2003;26(2):360-366. doi:10.2337/diacare.26.2.360

23. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835-1844. doi:10.2337/dc12-0002

24. Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018;6(7):538-546. doi:10.1016/S2213-8587(18)30079-2

25. Zargar AH, Wani AI, Masoodi SR, Laway BA, Bashir MI. Mortality in diabetes mellitus—data from a developing region of the world. Diabetes Res Clin Pract. 1999;43(1):67-74. doi:10.1016/S0168-8227(98)00112-0

26. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2):194-202. doi:10.1001/jama.293.2.194
27. Coughlin SS, Call EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159(12):1160-1167. doi:10.1093/aje/kwh161

28. Lam EK, Batty GD, Huxley RR, et al; Asia Pacific Cohort Studies Collaboration. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann Oncol. 2011;22(3):730-738. doi:10.1093/annonc/mdq405

29. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98. doi:10.1038/nrendo.2017.151

30. Röder PV, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. Exp Mol Med. 2016;48:e219. doi:10.1038/emm.2016.6

31. Baena-Díez JM, Peñafiel J, Subirana I, et al; FRESCO Investigators. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care. 2016;39(11):1987-1995. doi:10.2337/dc16-0614

32. Peters SAE, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542-1551. doi:10.1007/s00125-014-3260-6

33. Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014;383(9933):1973-1980. doi:10.1016/S0140-6736(14)60040-4

34. Peters SAE, Woodward M. Sex differences in the burden and complications of diabetes. Curr Diab Rep. 2018;18(6):33. doi:10.1007/s11892-018-1005-5

35. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care. 2003;26(11):2999-3005. doi:10.2337/diacare.26.11.2999

36. Shin WY, Kim HC, Lee T, et al. Combined effects of diabetes and low household income on mortality: a 12-year follow-up study of 505 677 Korean adults. Diabet Med. 2018;35(10):1345-1354. doi:10.1111/dme.13695

37. Ma S, Cutter J, Tan CE, Chew SK, Tai ES. Associations of diabetes mellitus and ethnicity with mortality in a multiethnic Asian population: data from the 1992 Singapore National Health Survey. Am J Epidemiol. 2003;158(6):543-552. doi:10.1093/aje/kwg199

**SUPPLEMENT.**

eAppendix. Descriptions of Participating Cohorts
eReferences
eTable 1. ICD-9 and ICD-10 Codes for Causes of Death
eTable 2. Number of Cause-Specific Deaths Among Patients With Diabetes vs in Non-Diabetic Populations: Stratified by Individual Characteristics in Asian Populations
eTable 3. All-Cause and Cause-Specific Mortality Associated With Diabetes: Sensitivity Analyses Excluding Subjects With a History of Cardiovascular Diseases and Any Cancers at Baseline
eTable 4. Hazard Ratios (95% CIs) for All-Cause and Cause-Specific Mortality Associated With Diabetes: Sensitivity Analyses Excluding One Country at a Time
eFigure. All-Cause Mortality Associated With Diabetes in Each Participating Cohort